Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study

BACKGROUND/AIMS: Only moderate to severe Crohn's Disease (CD) patients without a satisfactory conventional therapy effect are eligible to get reimbursement from the National Health Insurance of Taiwan for using adalimumab. These are more stringent criteria than in many Western countries and Jap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chang, Chen-Wang, Wei, Shu-Chen, Chou, Jen-Wei, Hsu, Tzu-Chi, Chuang, Chiao-Hsiung, Lin, Ching-Pin, Hsu, Wen-Hung, Yen, Hsu-Heng, Lin, Jen-Kou, Fang, Yi-Jen, Wang, Horng-Yuan, Lin, Hung-Hsin, Wu, Deng Cheng, Ni, Yen Hsuan, Wang, Cheng-Yi, Wong, Jau-Min
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Association for the Study of Intestinal Diseases 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4214955/
https://ncbi.nlm.nih.gov/pubmed/25374494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2014.12.4.287
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados